Benzinga - Gainers
- Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider.
- First Citizens BancShares, Inc. (NASDAQ: FCNCA) shares surged 42.5% to $829.82 after First-Citizens Bank & Trust Company entered an agreement to purchase all deposits and loans of Silicon Valley Bank.
- Alpine Acquisition Corporation (NASDAQ: REVE) surged 32% to $14.17.
- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) shares jumped 30% to $1.93 after gaining 8% on Friday.
- Jounce Therapeutics, Inc. (NASDAQ: JNCE) gained 23% to $1.86. Jounce Therapeutics entered into agreement to be acquired by Concentra Biosciences for $1.85 in cash per share plus contingent value rights.
- Silvergate Capital Corporation (NYSE: SI) gained 21.5% to $2.09. Silvergate Capital shares jumped 52% on Friday as traders circulated a rumor that a crypto exchange is trying to buy the company's trade processing technologies.
- Cimpress plc (NASDAQ: CMPR) jumped 21.4% to $37.91. Truist Securities maintained Cimpress with a Buy and raised the price target from $45 to $50.
- Gorilla Technology Group Inc. (NASDAQ: GRRR) surged 20.5% to $9.81.
- Pyxis Oncology, Inc. (NASDAQ: PYXS) gained 20.4% to $2.66. Pyxis Oncology recently reported loss of $3.65 per share in FY22.
- Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) rose 20.2% to $0.5248. Cyclerion Therapeutics received US FDA orphan drug designation for Zagociguat for treatment of mitochondrial diseases.
- FG Financial Group, Inc. (NASDAQ: FGF) rose 20% to $2.58 after posting a narrower quarterly loss.
- Delcath Systems, Inc. (NASDAQ: DCTH) gained 19.8% to $5.80 after reporting Q4 results. The FDA has accepted the company’s New Drug Application resubmission for HEPZATO Kit (melphalan hydrochloride for injection/hepatic delivery system) seeking approval for unresectable hepatic-dominant metastatic ocular melanoma.
- Berkshire Grey, Inc. (NASDAQ: BGRY) jumped 19.4% to $1.3606 as the company entered into definitive merger agreement with SoftBank Group for a go-private transaction.
- Loop Industries, Inc. (NASDAQ: LOOP) gained 17.9% to $2.24.
- First Republic Bank (NYSE: FRC) shares climbed 15.9% to $14.32 in sympathy with Silicon Valley Bank after First Citizens BancShares announced it will purchase all loans and certain other assets of SVB.
- Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) gained 12.9% to $1.75. The FDA will hold an Advisory Committee meeting to discuss the company’s application for NurOwn for amyotrophic lateral sclerosis.
- Blackbaud, Inc. (NASDAQ: BLKB) gained 12.9% to $65.32 over reports of a possible takeover offer. However, after reviewing the offer, Blackbaud's board rejected the non-binding proposal from Clearlake Capital Group, L.P., to acquire all of the company's outstanding shares for $71.00 per share in cash.
- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) shares rose 11.7% to $6.18. Iovance Biotherapeutics completed Biologics License Application submission for Lifileucel in advanced melanoma.
- Roku, Inc. (NASDAQ: ROKU) gained 8.6% to $65.17. Susquehanna upgraded Roku from Neutral to Positive and announced a $75 price target.
- Harrow Health, Inc. (NASDAQ: HROW) climbed 7.8% to $19.87. The company recently posted upbeat quarterly earnings.
- CytomX Therapeutics, Inc. (NASDAQ: CTMX) rose 7.1% to $1.82. CytomX Therapeutics is expected to report full year 2022 financial results on Monday, March 27, 2023, after the closing bell.
- Novartis AG (NYSE: NVS) surged 7% to $89.42 after the company announced positive results from a trial of its breast cancer treatment.
- KeyCorp (NYSE: KEY) climbed 5% to $12.44. Citigroup upgraded KeyCorp from Neutral to Buy and announced a $20 price target.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
Losers- Unity Biotechnology, Inc. (NASDAQ: UBX) shares dipped 46.3% to $2.23 after the company said its phase 2 ENVISION study did not meet its non-inferiority threshold due to strength in the control group.
- Near Intelligence, Inc. (NASDAQ: NIR) shares tumbled 25.5% to $9.07.
- Pharming Group N.V. (NASDAQ: PHAR) fell 18.9% to $12.31. The FDA approved Pharming Group’s Joenja (leniolisib) for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.
- Virios Therapeutics, Inc. (NASDAQ: VIRI) fell 12.4% to $0.3899 after jumping around 44% on Friday.
- Bird Global, Inc. (NASDAQ: BRDS) fell 11.2% to $0.1331 after gaining over 5% on Friday.
- YS Biopharma Co., Ltd. (NASDAQ: YS) dropped 10.6% to $4.2819 after the company reported interim Phase 2 safety and immunogenicity data for its PIKA recombinant Covid-19 vaccine.
- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) dipped 10.5% to $6.79. ARS Pharmaceuticals recently posted a FY22 loss of $0.87 per share.
- Ribbon Communications Inc. (NASDAQ: RBBN) dropped 10% to $3.3750.
- Boxed, Inc. (NYSE: BOXD) shares fell 9.8% to $0.2194 after dropping over 29% on Friday.
- Vigil Neuroscience, Inc. (NASDAQ: VIGL) dropped 9.8% to $11.01. Morgan Stanley maintained Vigil Neuroscience with an Equal-Weight and raised the price target from $12 to $13.
- Frontier Communications Parent, Inc. (NASDAQ: FYBR) fell 9.1% to $21.42. Frontier partnered with YouTube TV to deliver internet & tv experience. Morgan Stanley downgraded Frontier Communications from Equal-Weight to Underweight and lowered the price target from $23 to $19.
- Loop Media, Inc. (NYSE: LPTV) fell 8.3% to $5.03.
- PepGen Inc. (NASDAQ: PEPG) dropped 8.1% to $14.00. PopGen recently reported Q4 and full year 2022 financial results.
- Motorsport Games Inc. (NASDAQ: MSGM) fell 7% to $6.22 after the company posted downbeat results for its fourth quarter on Friday.
- Pear Therapeutics, Inc. (NASDAQ: PEAR) shares fell 6.7% to $0.2703 after jumping over 15% on Friday.
- Coinbase Global, Inc. (NASDAQ: COIN) dropped 6.6% to $63.32 after Barclays maintained an Equal-Weight rating on the stock and lowered its price target from $86 to $70.
3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or
remove ads
.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.